Overall, the use of the GLP-1 receptor agonist-SGLT-2 inhibitor combination was associated with a 30% lower risk of MACE (7.0 v 10.3 per 1000 person years
doi: 10.3109/07420528509055889 27 MochelJPFinkMPeyrouMDesevauxCDeurinckMGiraudelJMet al
It helps regulate blood sugar levels and controls appetite
Of those reporting no SGLT2i use at baseline, increasing numbers of participants started SGLT2i during the trial, with a greater proportion starting SGLT2i in the placebo (approximately 10% at 18 months and approximately 20% at 36 months) than in the semaglutide group (approximately 5% at 18 months and approximately 10% at 36 months
Of course, counting calories is not especially fun, but even doing so for a short period, like a week or two, can open your eyes to how much you actually eat in a day and how much less you can eat while still being satisfied
Likewise, Novo Nordisk which makes Ozempic also makes Wegovy, another semaglutide that is FDA-approved for weight loss